BC007, a peptide therapy developed by Berlin Cures, has gained regulatory approval in more than 30 countries for treating long COVID, yet the FDA remains hesitant. The compound targets autoantibodies that damage the cardiovascular and nervous systems in long COVID patients, offering a potential treatment where few alternatives exist.

The FDA's primary concern centers on the peptide's mechanism of action and long-term safety data. Regulators worry about unintended immune effects from removing autoantibodies, particularly regarding how the treatment affects the body's natural defense systems over extended periods. This caution reflects standard FDA protocol for immunomodulatory drugs, which require robust evidence of both efficacy and safety.

BC007 works by binding to and neutralizing autoantibodies that attack angiotensin II type 1 receptors and beta-1 adrenergic receptors. Long COVID patients often produce these harmful antibodies, which contribute to persistent symptoms like fatigue, heart dysfunction, and neurological complications. Early trial data showed promise, with patients reporting symptom improvement and objective markers of reduced cardiac dysfunction.

The regulatory disconnect highlights how approval standards vary globally. European and other regulatory bodies assessed BC007's risk-benefit profile differently than the FDA, allowing market access based on available evidence. This creates frustration among long COVID patients and researchers who see the therapy as potentially transformative for a condition that affects millions and lacks established treatments.

Berlin Cures continues working with the FDA to address outstanding questions. The company has submitted additional data and may need to conduct larger trials or longer follow-up studies to satisfy American regulators. The timeline for potential FDA approval remains uncertain.

For now, patients seeking BC007 must travel internationally or participate in ongoing clinical trials. The situation underscores the gap between global medical innovation and American regulatory approval, particularly for rare or emerging conditions where robust trial data takes years to accumulate